Predictors of Success of Phase II Pediatric Oncology Clinical Trials. (26th February 2019)

• Record Type: Journal Article
• Authors: Franshaw, Laura; Tsoli, Maria; Byrne, Jennifer; Mayoh, Chelsea; Sivarajasingam, Siva; Norris, Murray; Marshall, Glenn M.; Ziegler, David S.
• Is Part Of: Oncologist. Volume 24:Number 8(2019)
• Page Start: e765
• Page End: e774
• Publication Date: 2019-02-26
• Subjects: Phase II -- Pediatric -- Oncology -- Success -- Predictors; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2017-0666
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: There are limited data to predict which novel childhood cancer therapies are likely to be successful. To help rectify this, we sought to identify the factors that impact the success of phase II clinical trials for pediatric malignancies. Materials and Methods: We examined the impact of 24 preclinical and trial design variables for their influence on 132 phase II pediatric oncology clinical trials. Success was determined by an objective assessment of patient response, with data analyzed using Fisher's exact test, Pearson's chi‐square test, and logistic regression models. Results: Trials that evaluated patients with a single histological cancer type were more successful than those that assessed multiple different cancer types (68% vs. 47%, 27%, and 17% for 1, 2–3, 4–7, and 8+; p < .005). Trials on liquid or extracranial solid tumors were more successful than central nervous system or combined trials (70%, 60%, 38%, and 24%; p < .005), and trials of combination therapies were more successful than single agents (71% vs. 28%; p < .005). Trials that added therapies to standard treatment backbones were more successful than trials testing novel therapies alone or those that incorporated novel agents ( p < .005), and trials initiated based on the results of adult studies were less likely to succeed ( p < .05). For 61% of trials (80/132), we were unable to locate any relevant preclinical findings to support the trial. When preclinical studies were carried out (52/132), there was no evidence that the conduct of any preclinical experiments made the trial more likely to succeed ( p < .005). Conclusion: Phase II pediatric oncology clinical trials that examine a single cancer type and use combination therapies have the highest possibility of clinical success. Trials building upon a standard treatment regimen were also more successful. The conduct of preclinical experiments did not improve clinical success, emphasizing the need for a better understanding of the translational relevance of current preclinical testing paradigms. Abstract : Considering the limitations in understanding of how preclinical research and trial design influences clinical trial success, this article assesses factors that potentially may predict the success of phase II pediatric oncology clinical trials .